Palisade Bio Q3 EPS $(0.49) Misses $(0.34) Estimate
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio reported Q3 losses of $0.49 per share, missing the analyst consensus estimate of $0.34 by 44.12%. This is a 87.75% increase over losses of $4.00 per share from the same period last year.
November 10, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Palisade Bio's Q3 earnings missed analyst estimates by 44.12%, reporting losses of $0.49 per share.
Palisade Bio reported a larger than expected loss for Q3, missing analyst estimates by a significant margin. This could negatively impact investor sentiment and potentially lead to a short-term decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100